Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesNewsfile Corp • Tuesday
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MANewsfile Corp • Monday
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNewsfile Corp • 09/09/24
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateNewsfile Corp • 08/14/24
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL CompoundNewsfile Corp • 08/06/24
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross ProceedsNewsfile Corp • 07/12/24
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762Newsfile Corp • 07/08/24
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-agingNewsfile Corp • 06/18/24
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762Newsfile Corp • 05/28/24
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)Newsfile Corp • 05/23/24
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation StudyGlobeNewsWire • 05/15/24
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)GlobeNewsWire • 04/30/24
Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsGlobeNewsWire • 04/22/24
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)GlobeNewsWire • 04/16/24
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)GlobeNewsWire • 04/11/24
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdateGlobeNewsWire • 04/02/24
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchGlobeNewsWire • 03/13/24
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin DisordersGlobeNewsWire • 03/06/24
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesGlobeNewsWire • 01/31/24